P
Personal Genome Diagnostics (PGD)
Empowering the fight against cancer by unlocking actionable information from the genome
About Personal Genome Diagnostics (PGD)
Personal Genome Diagnostics (PGD), now a subsidiary of Labcorp, operates at the forefront of precision oncology, developing and commercializing a portfolio of genomic testing products for cancer. The company was founded in 2010 as a spin-out from Johns Hopkins University by Dr. Luis Diaz and Dr. Victor Velculescu, internationally recognized pioneers in cancer genomics who performed the first genome-wide sequence analyses in human cancers. Their research in next-generation sequencing (NGS) and the development of non-invasive "liquid biopsy" techniques formed the company's scientific foundation.
PGD's business model centers on providing both services and kitted in-vitro diagnostic (IVD) products to clinical laboratories, health systems, and biopharmaceutical companies. This strategy aims to decentralize cancer genomic profiling, allowing tests to be performed locally and results delivered more quickly, rather than relying on a centralized lab. Revenue is generated through the sale of these regulated diagnostic kits and by offering genomic analysis services to support pharmaceutical and biotechnology partners in clinical trials and companion diagnostic development.
The company's flagship offering is the PGDx elio™ portfolio, which includes both tissue-based and liquid biopsy tests. The PGDx elio™ tissue complete product, which received FDA clearance in April 2020, is a comprehensive genomic profiling kit that analyzes over 500 genes from tumor tissue to identify various genetic alterations, microsatellite instability (MSI), and tumor mutation burden (TMB). This was the first diagnostic kit of its kind cleared for use by any laboratory in the country, a significant milestone that facilitates broader access to precision oncology. The portfolio also includes liquid biopsy tests, such as PGDx elio™ plasma complete, which analyze circulating tumor DNA from a blood sample, offering a non-invasive method for genomic profiling.
The company's journey has been marked by substantial financial and strategic milestones, including a $21.4 million Series A in 2015, a $75 million Series B in 2018 co-led by Bristol-Myers Squibb, and a $103 million Series C in 2021. These funding rounds supported product development, global commercialization, and expansion of partnerships. In December 2021, Labcorp announced its acquisition of PGDx for $450 million, with up to an additional $125 million in milestone payments, a deal that was finalized in February 2022. This acquisition integrates PGDx's decentralized testing platforms with Labcorp's extensive diagnostic and drug development capabilities.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2010
- Headquarters
- Baltimore, United States
- Employees
- 65
- Open positions
- None listed
- Dealroom signal
- 64.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, DNA, Genetics and genomics, Spinout, Genome Engineering, Tech for Biotech and Pharma, Biotech and Pharma, medical testing, DT and LS
- Business model
- Manufacturing
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2021 | $575M | $575M | LabCorp | ↗ |
| SERIES COther financing | Feb 2021 | $103M | $412M | Windham Venture Partners · PFM Health Sciences · Innovatus Capital Partners · Vensana Capital | — |
Growth signals
Latest recorded traffic for Personal Genome Diagnostics (PGD) is 1.8K monthly website visits, up 38.5% over the last three months. Personal Genome Diagnostics (PGD)'s team declined 13.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Personal Genome Diagnostics (PGD) in the Baltimore ecosystem
The Personal Genome Diagnostics (PGD) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
NEA
Windham Venture Partners
3B Future Health Fund
Bristol-Myers Squibb
Maryland Venture Fund
Series B and later9 investors entered at this stage
Innovatus Capital Partners
PFM Health Sciences
Vensana Capital
Catalio Capital Management
Sands Capital Management
Rock Springs Capital
Northpond Ventures- CICowen Healthcare Investments
- KCKern Capital
Other known investors2 additional known investors
Johns Hopkins University
LabCorp
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Personal Genome Diagnostics (PGD) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Personal Genome Diagnostics (PGD)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









